Latest filing published 02 Jun 2023 for Vir Biotechnology, Inc., €60k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Steven J. Rice: trading record in brief
Steven J. Rice (senior executive) discloses dealings in Vir Biotechnology, Inc. to SEC (Form 4). In total, 13 filings cover trades dated from 16 February 2021 to 1 June 2023.
Sales make up the whole of the open-market record (7 sales, €1.1M). Other entries cover 3 share grants and 3 option exercises. Since January 2023: no purchases and 3 sales on the market.
On 2 June 2023 came the latest disclosure, an open-market sale for €60k in Vir Biotechnology, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Steven J. Rice
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,500 shares@ US$25.679.9% of flowCommon StockSEC:0001209191-23-033551:0
- 73,000 shares0Common StockSEC:0001209191-23-012994:0
- 1,981 shares@ US$25.2887.8% of flowCommon StockSEC:0001209191-23-011385:0
- 20,000 shares0Common StockSEC:0001209191-22-012953:0
- 1,942 shares@ US$31.931214.2% of flowCommon StockSEC:0001209191-22-011750:0
- 10,000 shares@ US$12.7629.5% of flowCommon StockSEC:0001209191-21-067656:0
- 10,000 shares@ US$12.7628.4% of flowCommon StockSEC:0001209191-21-053237:0
- 3 shares@ US$12.760.0% of flowCommon StockSEC:0001209191-21-043698:0
8 of 8 declarations
